86 related articles for article (PubMed ID: 22994781)
1. Oxaliplatin sensitizes OS cells to TRAIL-induced apoptosis via down-regulation of Mcl1.
Huang T; Gong WH; Li XC; Zou CP; Jiang GJ; Li XH; Qian H
Asian Pac J Cancer Prev; 2012; 13(7):3477-81. PubMed ID: 22994781
[TBL] [Abstract][Full Text] [Related]
2. The multikinase inhibitor sorafenib potentiates TRAIL lethality in human leukemia cells in association with Mcl-1 and cFLIPL down-regulation.
Rosato RR; Almenara JA; Coe S; Grant S
Cancer Res; 2007 Oct; 67(19):9490-500. PubMed ID: 17909059
[TBL] [Abstract][Full Text] [Related]
3. The coffee diterpene kahweol sensitizes TRAIL-induced apoptosis in renal carcinoma Caki cells through down-regulation of Bcl-2 and c-FLIP.
Um HJ; Oh JH; Kim YN; Choi YH; Kim SH; Park JW; Kwon TK
Chem Biol Interact; 2010 Jun; 186(1):36-42. PubMed ID: 20403343
[TBL] [Abstract][Full Text] [Related]
4. Proteasome inhibitor MG132 enhances TRAIL-induced apoptosis and inhibits invasion of human osteosarcoma OS732 cells.
Li X; Huang T; Jiang G; Gong W; Qian H; Zou C
Biochem Biophys Res Commun; 2013 Sep; 439(2):179-86. PubMed ID: 23994633
[TBL] [Abstract][Full Text] [Related]
5. Efficient killing effect of osteosarcoma cells by cinobufacini and cisplatin in combination.
Huang T; Gong WH; Li XC; Zou CP; Jiang GJ; Li XH; Qian H
Asian Pac J Cancer Prev; 2012; 13(6):2847-51. PubMed ID: 22938471
[TBL] [Abstract][Full Text] [Related]
6. P53-mediated upregulation of DcR1 impairs oxaliplatin/TRAIL-induced synergistic anti-tumour potential in colon cancer cells.
Toscano F; Fajoui ZE; Gay F; Lalaoui N; Parmentier B; Chayvialle JA; Scoazec JY; Micheau O; Abello J; Saurin JC
Oncogene; 2008 Jul; 27(30):4161-71. PubMed ID: 18345033
[TBL] [Abstract][Full Text] [Related]
7. Oxaliplatin sensitizes human colon cancer cells to TRAIL through JNK-dependent phosphorylation of Bcl-xL.
El Fajoui Z; Toscano F; Jacquemin G; Abello J; Scoazec JY; Micheau O; Saurin JC
Gastroenterology; 2011 Aug; 141(2):663-73. PubMed ID: 21683075
[TBL] [Abstract][Full Text] [Related]
8. Carnosic acid sensitized TRAIL-mediated apoptosis through down-regulation of c-FLIP and Bcl-2 expression at the post translational levels and CHOP-dependent up-regulation of DR5, Bim, and PUMA expression in human carcinoma caki cells.
Jung KJ; Min KJ; Bae JH; Kwon TK
Oncotarget; 2015 Jan; 6(3):1556-68. PubMed ID: 25596735
[TBL] [Abstract][Full Text] [Related]
9. Roscovitine sensitizes breast cancer cells to TRAIL-induced apoptosis through a pleiotropic mechanism.
Ortiz-Ferrón G; Yerbes R; Eramo A; López-Pérez AI; De Maria R; López-Rivas A
Cell Res; 2008 Jun; 18(6):664-76. PubMed ID: 18458681
[TBL] [Abstract][Full Text] [Related]
10. Dovitinib sensitizes hepatocellular carcinoma cells to TRAIL and tigatuzumab, a novel anti-DR5 antibody, through SHP-1-dependent inhibition of STAT3.
Chen KF; Chen HL; Liu CY; Tai WT; Ichikawa K; Chen PJ; Cheng AL
Biochem Pharmacol; 2012 Mar; 83(6):769-77. PubMed ID: 22230479
[TBL] [Abstract][Full Text] [Related]
11. Galangin sensitizes TRAIL-induced apoptosis through down-regulation of anti-apoptotic proteins in renal carcinoma Caki cells.
Han MA; Lee DH; Woo SM; Seo BR; Min KJ; Kim S; Park JW; Kim SH; Choi YH; Kwon TK
Sci Rep; 2016 Jan; 6():18642. PubMed ID: 26725939
[TBL] [Abstract][Full Text] [Related]
12. Bcl-xL inhibition by molecular-targeting drugs sensitizes human pancreatic cancer cells to TRAIL.
Hari Y; Harashima N; Tajima Y; Harada M
Oncotarget; 2015 Dec; 6(39):41902-15. PubMed ID: 26506422
[TBL] [Abstract][Full Text] [Related]
13. Oxaliplatin enhances TRAIL-induced apoptosis in gastric cancer cells by CBL-regulated death receptor redistribution in lipid rafts.
Xu L; Qu X; Zhang Y; Hu X; Yang X; Hou K; Teng Y; Zhang J; Sada K; Liu Y
FEBS Lett; 2009 Mar; 583(5):943-8. PubMed ID: 19223002
[TBL] [Abstract][Full Text] [Related]
14. Se-methylselenocysteine sensitized TRAIL-mediated apoptosis via down-regulation of Bcl-2 expression.
Lee JT; Lee TJ; Park JW; Kwon TK
Int J Oncol; 2009 May; 34(5):1455-60. PubMed ID: 19360359
[TBL] [Abstract][Full Text] [Related]
15. ABT-263 sensitizes TRAIL-resistant hepatocarcinoma cells by downregulating the Bcl-2 family of anti-apoptotic protein.
Wang G; Zhan Y; Wang H; Li W
Cancer Chemother Pharmacol; 2012 Mar; 69(3):799-805. PubMed ID: 22037880
[TBL] [Abstract][Full Text] [Related]
16. Epigallocatechin-3-gallate Sensitizes Human 786-O Renal Cell Carcinoma Cells to TRAIL-Induced Apoptosis.
Wei R; Zhu G; Jia N; Yang W
Cell Biochem Biophys; 2015 May; 72(1):157-64. PubMed ID: 25539708
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of Cathepsin S Induces Mitochondrial ROS That Sensitizes TRAIL-Mediated Apoptosis Through p53-Mediated Downregulation of Bcl-2 and c-FLIP.
Seo BR; Min KJ; Woo SM; Choe M; Choi KS; Lee YK; Yoon G; Kwon TK
Antioxid Redox Signal; 2017 Aug; 27(4):215-233. PubMed ID: 27927016
[TBL] [Abstract][Full Text] [Related]
18. Triptolide sensitizes resistant cholangiocarcinoma cells to TRAIL-induced apoptosis.
Panichakul T; Intachote P; Wongkajorsilp A; Sripa B; Sirisinha S
Anticancer Res; 2006; 26(1A):259-65. PubMed ID: 16475706
[TBL] [Abstract][Full Text] [Related]
19. Mcl-1: a gateway to TRAIL sensitization.
Kim SH; Ricci MS; El-Deiry WS
Cancer Res; 2008 Apr; 68(7):2062-4. PubMed ID: 18381408
[TBL] [Abstract][Full Text] [Related]
20. Platinum(IV) complex LA-12 exerts higher ability than cisplatin to enhance TRAIL-induced cancer cell apoptosis via stimulation of mitochondrial pathway.
Jelínková I; Šafaříková B; Vondálová Blanářová O; Skender B; Hofmanová J; Sova P; Moyer MP; Kozubík A; Kolář Z; Ehrmann J; Hyršlová Vaculová A
Biochem Pharmacol; 2014 Dec; 92(3):415-24. PubMed ID: 25285768
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
